DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for atrophoderma vermiculata — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAtrophoderma vermiculata maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for atrophoderma vermiculata is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Russian Journal of Skin and Venereal Diseases · 2020 · 1 citations · open access
AbstractAtrophoderma vermiculata is a rare, benign, follicular dermatosis localized in an esthetically important facial skin zone, which results in superficial scars formation. The disease usually occurs at the age of 512 years and may be autosomal-dominantly inherited. This type of dermatosis may be associated with other congenital abnormalities and some hereditary diseases, such as Marfan syndrome, neurofibromatosis, congenital heart defects, and mental retardation similar to Downs syndrome. The authors also analyze the typical clinical presentations of atrophoderma vermiculata, from their own clinical experience, conduct a detailed analysis of differential diagnosis with other dermatoses, and provide contemporary therapeutic methods and approaches to this skin disorder.
GLOBAL JOURNAL FOR RESEARCH ANALYSIS · 2023 · 0 citations · open access
ATROPHODERMA VERMICULATUM: A RARE CASE WITH ISOLATED PRESENTATION
AbstractAtrophoderma vermiculata is a rare and benign follicular disorder of the skin occurs due to abnormal keratinisation in follicular pilosebaceous unit. It presents as multiple, symmetric, depressed pitted scars with reticular/ honeycomb atrophy of skin. It usually presents in face but in our case lesions are seen over chest, back, shoulder and gluteal region. The onset is mostly sporadic or sometimes inherited Autosomal Dominant. It is a clinical variant of Keratosis Pilaris Atrophicans. This condition is difcult to treat cosmetically. Hereby we report a rare case of Atrophoderma Vermiculatum with isolated presentation and different site involvement, treated with oral Isotretinoin showing good response
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
